The New England journal of medicine
-
Comment Letter
Diagnosis and Management of the Antiphospholipid Syndrome.
-
Randomized Controlled Trial Multicenter Study
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined. ⋯ In a high-risk population of overweight or obese patients, lorcaserin facilitated sustained weight loss without a higher rate of major cardiovascular events than that with placebo. (Funded by Eisai; CAMELLIA-TIMI 61 ClinicalTrials.gov number, NCT02019264 .).